Thalidomide derivatives degrade BCL-2 by reprogramming the binding surface of CRBN

• DOI: 10.1016/j.xcrp.2024.101960
• Publication Date: 2024-05-02T14:45:52Z
• Authors: Jianhui Wang; Marcel Heinz; Kang Han; Varun J. Shah; Sebastian Hasselbeck; Martin P. Schwalm; Rajeshwari Rathore; Gerhard Hummer; Jun Zhou; Ivan Dikic; Xinlai Cheng
• Keywords: 0301 basic medicine; 03 medical and health sciences

Recent studies demonstrate that modified thalidomide chemically alters the binding surface of its binding E3 ligase, CRBN, leading to the degradation of new substrate proteins. In this study, we conduct a proteome-wide analysis of thalidomide-like compounds and pinpoint three derivatives (C5, C6, and C7) that specifically target and degrade the BCL-2 protein. Using AlphaFold-driven molecular modeling combined with experimental data, we suggest that GLY128, ALA131, and THR132 are crucial in forming a CRBN-C5-BCL-2 ternary complex. This interaction is notably distinct from that of venetoclax, a known clinical BCL-2 inhibitor that interacts with the BH3 domain. Significantly, these thalidomide derivatives have the ability to degrade BCL-2 mutations that are resistant to venetoclax, thereby enhancing survival rates in a Notch-depleted Drosophila intestinal tumor model. Our findings highlight the critical role of targeted modifications to the E3 ligase surface in altering its binding affinity and achieving a new substrate protein profile.